Abbvie Inc ABBV

$285.99 -0.40 (-0.14%)

Valuation

Market cap
466,362,624,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.29
Forward PE
20.51
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
3,111,349
Avg volume
4,600,436
Day's range
$281.23 – $288.80
Shares out
1,766,793,000
Stochastic %K
62%
Beta
0.29
Analysts
Strong Sell
Price target
$284.40

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

DG20 Oct 29, 3:31 AM
$ABBV $AZN $NVO $VKTX VK2735 is over 11 months since last clinical trial update. Strongly suggests that they have been no safety signals to date. Ph3 data ~ 9 months away and likely to present BIC weightloss for a GLP/GIP dual agonist and potentially industry leading tolerability especially with extended dosing.
1 replies
biolover Oct 29, 2:45 AM
U got people commenting on a mature phase 3 trial where all pts received > 1 year of $VKTX 2735 as long way to go while others such as $AZN , $NVO etc are doing preclinical deals.😂 $ABBV that is looking at obesity as its primary growth driver barely started phase 2 with a mediocre asset. Who cares about commercializing or not. Worst case just wait for phase 3 and either stay or get out.
1 replies
55X_ROI_Q1_2026 Oct 28, 11:37 PM
$SLS $ABBV the IDMC Unblinded Actual Phase 3 Median Overall Survival, Median Follow-up and Immune Response Data from the Interim Analysis at 60 Events- So they have much of the Data Already Tabulated / compiled. -- SLS share Price Doubled the Day the Unblinded MOS and IR data was announced - even with a Major offering. • All Pooled MOS was not Reached > 13.5 months • Not Futile • Gps Elicted a WT1 Specific Immune Response in 80% of tested Patients. • Immune response is Directly Correlated with Extended 2x 3x 4x Survival in ALL PRIOR GPS Trials. //
0 replies
55X_ROI_Q1_2026 Oct 28, 10:34 PM
$SLS $ABBV The VIALE-M Phase 3 Trial conducted by ABBV was for Transplant Ineligible AML Patients in First Remission (CR1) - and Venclexta + ORAL Aza Failed to show increased Survival over OralAz alone (onureg). VEN + Aza Failed Transplant Ineligible AML First Remission Patients (CR1) Ven + Aza also Failed Transplant Ineligible AML Second Remission (CR2) Patients in the SLS Phase 3 Control ARM. Gps Phase 2 MOS > 67.6 Months in Transplant Ineligible First Remission vs Onureg / Oral Az 24.7 Months. It is not complicated.
0 replies
DefenseMania Oct 28, 9:56 PM
$ABBV $AMGN $GILD $EXEL Been dripping/buying these for many many years also PFE MDT 💰💰💰
0 replies
55X_ROI_Q1_2026 Oct 28, 8:51 PM
$SLS per the Nov. 2022 SAP, the FDA has agreed to Approve GPS with a Hazard Ratio of .636 or better at 80 events. it is as simple as that. And we all know now, BAT FAILED - BAT Failed to Increase survival 5 Recent and Large AML Trials conducted by $ABBV and MDACC. the Long Tail extended Survival is Gps - Doing what its done in ALL Prior trials; preventing relapse and meanigfully extending survival, including in 2 Phase 2 Trials for AML Remission with 2x and 4x OS Advantages, with pristine safety and correlated with Immune Response. These are the days to be Loading.
2 replies
maphere Oct 28, 8:07 PM
$RGNX $ABBV New Abbvie position for eyecare, key sentence: The role supports insights and analytics for upcoming Eye Care launches. https://careers.abbvie.com/en/job/senior-manager-market-research-and-analytics-eye-care-in-mettawa-il-jid-34986?utm_source=chatgpt.com/en
1 replies
55X_ROI_Q1_2026 Oct 28, 7:47 PM
$SLS $MRNA $ABBV ABBV Tried 8 Different Dosing Combinations - ALL FAILED. -- BAT Failed the VIALE-M - AML Patients in First Remission -- BAT also Failed the REGAL Phase 3 CONTROL ARM Patients in Second Remission
1 replies